Overdose with angiotensin II would be expected to result in hypertension, necessitating close monitoring and supportive care FDA Label. Effects are also expected to be brief as the half-life of angiotensin II is less than one minute FDA Label.
In the ATHOS-3 clinical study there was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received angiotensin II compared to placebo treated patients. The major imbalance was in deep venous thromboses - which prompts the potential need to use concurrent venous thromboembolism (VTE) prohphylaxis FDA Label.
Adverse effects of noticeable potential (>= 10%) include thromboembolic events (ie. like deep vein thrombosis) including arterial and venous thrombotic events, thrombocytopenia, tachycardia, and fungal infection. Effects whose potential are < 10% include delirium, acidosis, hyperglycemia, peripheral ischemia FDA Label.
Concomitant use of angiotensin converting enzymes (ACE) inhibitors may increase the response of angiotensin II FDA Label.
Concomitant use of angiotensin II blockers (ARBs) may decrease the response to angiotensin II FDA Label.
There are no formal data regarding the safe use of angiotensin II in pregnant women. However, septic or other distributive shock is a medical emergency that can be fatal if left untreated. Delaying treatment in pregnant women with hypotension associated with septic or otherdistributive shock is likely to increase the risk of maternal and fetal morbidity and mortality FDA Label.
There is no formal data regarding whether or not angiotensin II may become present in human milk and there is no data available on the effects of angiotensin II on the breastfed child or the effects on milk production FDA Label.
The safety and efficacy of angiotensin II in pediatric patients has not yet been established FDA Label.
There is no difference in the safety or efficacy between patients less than 65 years old and those 65 years or older when treated with angiotensin II FDA Label.
There is no difference in pharmacokinetics between male and female patients FDA Label.
The pharmacokinetics of angiotensin II are not expected to be influenced by renal impairment or hepatic impairment FDA Label.
Angiotensin II is under investigation for the treatment of Sepsis, Septic Shock, Diabetes Mellitus, and Acute Renal Failure. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy.
As of December 21, 2017 the FDA approved La Jolla Pharmaceutical's Giapreza (angiotensin II) Injection for Intravenouse Infusion for the indication of acting as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. The novelty of the medication lies in the fact that it is the first and only use of synthetic human angiotensin II to help maintain body blood pressure.
Shock is the inability to maintain blood flow to vital tissues and the potential resultant organ failure and death within hours, no matter young or o ld. As distributive shock is the most common type of shock in the inpatient setting and affects up to one third of patients in the intensive care unit, the FDA determined that there is a need for treatment options for critically ill hypotensive patients who do not adequately respond to currently available therapies.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Patent Blue | The risk or severity of hypotension can be increased when Patent Blue is combined with Angiotensin II. |
| Thyrotropin alfa | Thyrotropin alfa may increase the vasoconstricting activities of Angiotensin II. |
| Liothyronine | Liothyronine may increase the vasoconstricting activities of Angiotensin II. |
| Levothyroxine | Levothyroxine may increase the vasoconstricting activities of Angiotensin II. |
| Liotrix | Liotrix may increase the vasoconstricting activities of Angiotensin II. |
| Tiratricol | Tiratricol may increase the vasoconstricting activities of Angiotensin II. |
| Thyroid, porcine | Thyroid, porcine may increase the vasoconstricting activities of Angiotensin II. |
| Lidocaine | The risk or severity of hypertension can be increased when Angiotensin II is combined with Lidocaine. |
| Oxytocin | The risk or severity of hypertension can be increased when Angiotensin II is combined with Oxytocin. |
| Chloroprocaine | The risk or severity of adverse effects can be increased when Angiotensin II is combined with Chloroprocaine. |